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Coronary bifurcation lesions are frequently observed and remain a challenging patient 
population for successful treatment. Currently, the provisional approach of treatment is 
considered the first-line method of treatment. Many dedicated bifurcation stents and 
newer treatment approaches such as drug-coated balloons and bioresorbable scaffolds 
are also particularly attractive concepts. The aim of this article is to review the current 
treatment approaches for coronary bifurcation lesions, mainly the dedicated bifurcation 
stent systems while briefly covering the related topics of provisional and two-stent 
procedures of treatment and the current status of drug-coated balloons and 
bioresorbable scaffolds. This article highlights the critical trials involving these 
strategies. We searched PubMed, Google Scholar, Medline and ClinicalTrials.gov to 
identify all the relevant trials assessing the safety and efficacy of dedicated bifurcation 
stent systems, drug-coated balloons vs. other traditionally used coronary stents. A 
debate still prevails to treat coronary bifurcation lesions optimally. Provisional stenting 
strategy remains the gold standard for treating a majority of coronary bifurcation 
lesions, but the two-stent approach can be indicated for some lesions. More long-term 
follow-up trials are required to concretely define the role of newer treatment approaches 
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INTRODUCTION
Coronary bifurcation lesions (BIFs) are one of the most 
exciting and challenging pathologies of the coronary 
artery. They account for roughly 20% of all 
percutaneous coronary interventions (PCI) and are 
connected to lower procedural success and high rates of 
long-term major adverse cardiac events (MACE) [1, 2]. 
BIFs are so-referred to lesions occurring at, or adjacent 
to, a significant division of a major epicardial coronary 
artery. They vary anatomically, including the dynamic 
changes occurring during the cardiac cycle and in 
response to treatment [3]. Every single bifurcation is 
different. Hence, there is no only strategy applicable to 
every bifurcation [3]. Noteworthy improvements were 
made in the recent past regarding the understanding and 
treatment of BIFs. These include the introduction of 
drug-eluting stents, use of single stent techniques vs. 
two-stents, acceptance of a suboptimal result in the side-
branch (SB), etc [4]. 
 
 
Approaches to Bifurcation Treatment 
The simplified approaches as outlined in the Figure 1 
which is related with a low risk of failure and 
complications. 
Provisional Approach 
Considerable debate is ongoing over the last few years 
to ascertain the optimal stenting strategy for treating 
BIFs. Presently, the use of single-stent strategy 
(Provisional Strategy) is favored as the first choice of 
treatment of non-left main (LM) bifurcations in 
published trials [3, 5]. The reasons for the earlier stated 
preference is that the formal strategy is quick, easy to 
perform, safe, and shows similar results to a more 
complex technique [3]. Two appropriate approaches for 
provisional stenting are either using a pressure wire to 
interrogate the SB's lesion or performing kissing balloon 
inflation (FKI) on all angiographically significant SB 
lesions at the ostium [3]. However, SB occlusion post 
stenting of main vessel (MV) is one of the most frequent 
complications, encountered during bifurcation stenting. 
It appeared rational to accept that the prominent 
mechanism behind SB compromise is shifting of plaque 
from MV to SB (plaque shift) as the burden of plaque in 
MV and also in SB is the chief risk factor of SB 
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compromise [6, 7]. Although pre-dilation of the SB may 
be used, its advantage remains controversial.(8) On the 
above lines, Lee et al. from the new COBIS II registry 
investigated SB pre-dilation effects on procedural and 
long-term outcomes in coronary bifurcation lesions 
involving the provisional approach. This trial concluded 
that SB pre-dilation technique improved acute 
angiographic and procedural findings, but did not 
advance long-term clinical outcomes in case of actual 
bifurcation lesions [8]. 
Two-Stent Approach 
There is room to use elective two-stent techniques as 
well, to treat severely diseased large SB (like LM 
bifurcation lesions) supplying large area of myocardial 
volume and complex BIFs (calcified side branches with 
ostial disease extending 5 mm from carina, sharp 
angulated origin of side branch where there is 
anticipated difficulty in recrossing after main vessel 
stenting) to avoid acute hemodynamic compromise. 
However, none of these two-stent techniques are proven 
to be superior to others. To reduce the risk of SB 
occlusion and to improve patient outcomes, selection of 
proper bifurcation treatment strategy with the aid of 
intravascular ultrasound (IVUS) for SB ostium is 
fundamental [9, 10]. The most commonly used two-
stent approaches are double kissing (DK) crush, culotte, 
mini-crush, V and simultaneous kissing stent (SKS) [3, 
11]. As stated earlier, controversies still prevail 
regarding the use of sophisticated techniques. 
Currently, optimally performed two-stent techniques by 
using new-generation drug-eluting stents (DES) may 
provide similar or even better outcomes vs. the simple 
provisional methods [12]. 
Comparison of the Stenting Approaches 
Several landmark trials also need to be mentioned here 
in a more detailed form to evaluate the significance of 
the two strategies thoroughly (Table 1). 
The CACTUS was a prospective, randomized, 
multicenter study comparing elective “crush” stenting 
and sole stenting of the MB with provisional side-branch 
T-stenting with mandatory final kissing-balloon 
inflation (FKBI/FKI) in true BIFs. In this significant 
trial, 350 patients from 12 centers in Europe were 
enrolled. One hundred seventy-seven patients were 
enrolled in the Crush group, while 173 patients were 
included in the provisional arm. 94% of the lesions were 
defined to be true bifurcations out of which 75% lesions 
were classified as type 1,1,1 as per MEDINA method. It 
should be noted here that 31% of cases in the provisional 
group required additional stent implantation. No 
significant differences were found regarding the primary 
endpoint at 6-months follow-up: cumulative MACE 
rate was 15.8% in the Crush group vs. 15% in the 
provisional group. It should also be noted that the 
performance of FKI vs. no FKI was associated with a 
significantly lower incidence of in-hospital and follow-
up MI and angiographic restenosis in the MB and the SB 
in both the groups [13]. 
Thus, CACTUS demonstrated that a provisional 
strategy is useful with the additional necessity to implant 
a second stent in the SB for nearly 1/3rd patients [13]. 
To conclude, CACTUS supports the usual 
recommendation of using provisional stenting for 
coronary bifurcation lesions [4]. 
The prospective randomized NORDIC trial provided 
more definite evidence for using either one-stent or two-
stent technique with DES to treat bifurcation lesions. 
This landmark trial compared the strategy of stenting 
both the MB and SB vs. the provisional stenting of the 
MB only with sirolimus-eluting stents. The operator was 
required to attempt the FKI technique for all SB stenting 
cases at the end of the method. MACE after six months 
was the primary endpoint of the trial, which was not 
significantly different in both the groups after six 
months. After eight months, the combined angiographic 
endpoint of diameter stenosis > 50% of MV and 
occlusion of the SB was found in 5.3% in the provisional 
main branch stenting group and 5.1% in the two-stent 
group. To conclude, this trial suggests that the simple 
provisional stenting strategy used was associated with 
reduced procedure and fluoroscopy times and lower 
rates of procedure-related biomarker elevation. The 
study again highlights that most of the bifurcations can 
be treated with a provisional stenting strategy with an 
optional second stent. Also, a planned two-stent 
approach should be used for treating lesions with a large 
SB (like left main bifurcation) (Table 2) [14]. However, 
two-stent techniques are chosen more frequently for 
LM bifurcation than for non-LM lesions due to ischemic 
myocardial volume, which would be risk by adverse 
events [9]. In the DKCRUSH-V randomized trial, a 
planned DK crush two-stent strategy reduced target 
lesion failure (16.9% vs. 8.3%; P = 0.005) and stent 
thrombosis (4.1% vs. 0.4%; P = 0.006) compared with a 
provisional stenting for unprotected left main distal 
bifurcation lesions through 3-year follow-up [11]. 
To conclude, the success of the procedure itself is more 
dependent for positive long-term clinical outcomes than 
the type of stenting, underlining the greater importance 
of augmenting the preferred technique than the choice 
of method [9]. 
Dedicated Bifurcation Stents (DBS) 
Rationale for DBS 
As noted, the treatment approach for bifurcation PCI 
with either single or two stents is confusing, challenging 
and is subjected to several drawbacks. Hence, to 
overcome these deficiencies, some advanced stents 
dedicated for treating bifurcation lesions are now 
available. These newly available dedicated stents can be 
broadly classified as per below-mentioned Table 3. 
The below mentioned Table 4 explains the unique 
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design features along with the details of safety and 
effectiveness of currently known dedicated bifurcation 
stents to treat coronary bifurcation lesions. 
 
Table 1. Results of Provisional vs. Two-Stent Technique 
Reference 
Study 
Year Number of Patients FU (in 
Months) 
Adjusted Hazard Ratio/Comparative Rates (%) 
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2016 178 87 120 60% vs. 
66%, 
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14%, P > 
0.05 
--- --- 19% vs. 
25%, P > 
0.05 
Chen et al. 
[11] 














MACE: Major Adverse Cardiac Events; MI: Myocardial Infarction; TLR: Target Lesion Revascularization; TVR: Target Vessel Revascularization. 
 
Table 2. Preferred Strategy to Treat Bifurcation Lesions as Per Lesion Characteristics [9] 
Preferred Strategy (Lesion characteristics) 
Provisional 
1) Immaterial stenosis at the ostial LCX with MEDINA classification 1, 1, 0 or 1,0,0 
2) Small LCX <2.5 mm in diameter 
3) Little LCX, right dominant coronary system 
4) A wide angle between LAD and LCX 
5) No concomitant disease or only focal disease in LCX 
Two-stent approach 
1) Significant stenosis at the ostial LCX with MEDINA classification 1, 1, 1 or 1, 0, 1 or 0, 1, 1 
2) Large LCX ≥2.5 mm in diameter 
3) Diseased left dominant coronary system 
4) Narrow-angle between LAD and LCX 
5) Concomitant diffuse disease in LCX 
LAD: Left Anterior Descending; LCX: Left Coronary Circumflex 
 
Table 3. Classification of Current DBS [4] 
Purpose of Stents Some Available Stents Significance 
Stents for provisional SB stenting that enable 
or maintain access to the SB after MB stenting 
and do not need re-crossing of MB stent struts 
Petal (boston scientific), 
invatec (invatec), antares 
(trireme), y-med sidekick (y-
med Inc.), nile croco 
(minvasys), multilink 
frontier, (abbott vascular) 
Sanctions the second stent placement on the SB, if required 
Side-branch stenting followed by MB stent 
implantation in the bifurcation and requiring 
re-crossing 
Sideguard (Cappella Inc.), 
Tryton (Tryton medical), 
Axxess plus (Devax) 
Sideguard and Tryton are developed to treat the SB first. They 
need re-crossing into the SB after MB stenting. The Axxess 
plus is planted in the proximal MB at the level of the carina and 
does not need re-crossing into the SB but may require the 
additional implantation to treat some BIFs completely 
BIFs: Bifurcation Lesions; MB: Main Branch; SB: Side Branch 
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Table 4. Brief Information on Currently Available DBS 








Y-Med Sidekick Y-Med, USA 1) Low-profile 6F guide 
compatible SDS 2) SDS 
integrates an MB fixed-wire 
platform with a rapid-exchange 
steerable guidewire that 
preserves SB access 3) 
Available in 3 models with 




Ischinger, et al. 
2007 
Device success rate – 80%, additional stent 
Requirement – 40%, 1 MACE reported in a short-
term FU 
[4] 
Multilink Frontier Abbott 
Vascular, 
USA 
Balloon expandable, two 
balloons with simultaneous 
kissing inflation, two guidewire 




Device Success – 91%, Procedural Success – 93%. In-
hospital MI in 2 patients following SB occlusion Late 
loss - 0.84–0.55 mm, Overall bifurcation restenosis 
rate  44.8%, At 6-months FU, TLR – 13.3% and 





Single balloon and inflation, 
rapid exchange, peel away 
lumen for the second wire 







Double balloon and wire, 









Invatec, Italy Dual balloon, a single inflation Lefevre Angiographic success – High, Device Success – 75%. 
TLR at seven months – 14.3%, In conclusion, a trend 
for higher device success and better safety profile with 






Dual balloon, two catheters, 
Paclitaxel elution in the newer 
generation 
Del Blanco et al. Nile Croco Study demonstrated high performance 
and safety of Nile Croco stent system in treating 
bifurcation lesions, with a high procedural success 
rate and low prevalence of MACE. 
[21, 22] 





Dual balloon, dual wire, single 
inflation, Paclitaxel elution 
Ormiston et al. Successful implantation occurred in 89.3% of 
patients. On a per-device basis, 73.5% of deployments 
were successful. The primary endpoint occurred in 
one patient. TVR was 11.1%, TLR was 7.4%, and 
through 1-year, there were no deaths, Q-wave MIs, or 
stent thrombosis. In-segment late loss was 0.47 + or - 
0.45 mm (proximal MB), 0.41 + or - 0.57 mm (distal 
MB), and 0.18 + or - 0.39 mm (SB) as observed in 21 
patients. 
[21, 23] 
Stentys Stentys, USA Single wire, second, separate 
wire needed for SB, self-
expandable, Paclitaxel elution 




OPEN I demonstrated excellent procedural success 
with a relatively low MACE and competitively low 
LLL in both MB and SB at six months. Stentys 
demonstrated good intermediate procedure-related 
results with low AE rates at mid-term FU as per 
Cortese, et al. Stentys was termed safe and feasible 
also in case of PCI-STEMI with acceptable 1-year 
cardiovascular event rates, improving with post-








Single balloon, single wire Tryton Side 
Branch study,  
Genereux, et al. 
The Tryton Confirmatory Study along with 
TRYTON Pivotal RCT supports the safety and 
effectiveness of Tryton SBS for treating BIFs 








Single balloon, single wire, self-
expandable, nitinol-based 
Mamas, et al. The stent can be used to treat complex BIFs and is 
not affected by limitations stated with standard 
methods. 
[21, 27] 
Devax AXXESS™ Devax, USA Single wire, self-expandable, 
Biolimus A9 elution 
DIVERGE, 
Triantafyllis et al., 
Borgia, et al. 
Firstly, DIVERGE confirmed the safety and efficacy 
of AXXESS stent to treat BIFs. Then, Triantafyllis et 
al. stated that percutaneous revascularization of 
complex BIFs with the AXXESS stent is safe, 
providing excellent results at long-term, especially in 
non-LM lesions. Recently, the feasibility of AXXESS 








Dual balloon, dual wire, single 
inflation 
BRANCH BRANCH demonstrated the Medtronic Bifurcation 
Stent to be safe and effectively deployable to treat a 
plethora of BIFs with good clinical outcomes 
[21, 30] 
BiOSS Expert Balton, 
Poland 
Final kissing balloon inflation, 
paclitaxel elution 
POLBOS I MACE rates were comparable. TLR was higher with 
BiOSS Expert. A more aggressive protocol generated 
better outcomes 
[31] 
BiOSS LIM Balton, 
Poland 
Final kissing balloon inflation 
(FKBI), sirolimus elution 
POLBOS II MACE and TLR were comparable between BiOSS 
LIM and rDES. Cumulative MACE and TLR were 
also comparable at 12-month FU, FKBI subgroup of 
BiOSS LIM demonstrated significantly lower 
restenosis rates 
[32] 
AE: Adverse Event; BIFs: Bifurcation Lesions; FKBI/FKI: Final Kissing Balloon Inflation; FU: Follow-up; MACE: Major Adverse Cardiac Events; MB: 
Main Branch; MI: Myocardial Infarction; rDES: Recent Drug-Eluting Stents; LLL: Late Lumen Loss; PCI-STEMI: Percutaneous Coronary Intervention 
for ST-Elevation Myocardial Infarction; SB: Side Branch; SDS: SideKick dedicated system; TLR: Target Lesion Revascularization; TVR: Target Vessel 
Revascularization. 
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Table 5. Effectiveness of Drug-Coated Balloons in Coronary Bifurcation Lesions [5] 
Trial No. of 
Patients (n) 
Treatment DCB Used Main Results 
PEPCAD V 28 DCB in both branches + BMS in MB Sequent Please LLL: 0.38 ± 0.46 mm (MB) and 0.21 ± 0.48 mm (SB) 
DEBUIT 117 BMS in MB (37 patients) DCB in both branches 
+ BMS in MB (40 patients) DES in MB (40 
patients) 
Dior I In-segment LLL: -0.49 ± 0.85 mm -0.41 ± 0.60 mm -0.19 
± 0.64 mm, respectively, (p = 0.001) 
BABILON 108 DCB in both branches + BMS in MB (52 
patients) DES in MB (56 patients) 
Sequent Please In-segment LLL: -0.31 ± 0.48 mm -0.16 ± 0.38 mm (p = 
0.150) 
BIOLUX-I 35 DES in MB and DCB in SB Pantera Lux SB LLL 0.10 ± 0.43 mm 
DEBSIDE 50 DES in MB and DCB in SB Danubio SB LLL -0.04 ± 0.3 mm 




34 DCB+DES on the same vessel in 26.5% patients. 




TLR and MACE in 3 patients No adverse events were 
observed in patients treated for de novo lesions or BMS 
restenosis. This DCB (sirolimus) demonstrated high 
immediate technical performance and adequate short-
term efficacy and safety 
Sgueglia, et 
al. [34] 





No MACE, ISR reported 
BMS: Bare-Metal Stent; DCB: Drug-Coated Balloon; DES: Drug-Eluting Stent; ISR: In-Stent Restenosis; LLL: Late Luminal Loss; MACE: Major 
Adverse Cardiac Events; MB: Main Branch; MV: Main Vessel; SB: Side Branch 
 
 
Figure 1. Simplified Approach to Treat BIFs [1]. FFR: Fractional Flow Reserve; FKI: Final Kissing Balloon; POT: Proximal Optimization Technique; 
SB: Side Branch 
 
Other Available Techniques for Treating 
Bifurcation Lesions 
Use of Drug-Coated Balloons to Treat BIFs 
Drug-coated balloons (DCB) are a comparatively new 
technology, permitting the release of anti-proliferative 
agent discarding the concept of a permanent prosthesis. 
These are proved to be useful to treat in-stent restenosis 
and shown promise also to treat de novo small coronary 
vessel disease [5]. However, currently, the data available 
to determine its exact value remains scarce. Also, these 
data often demonstrate conflicting results. The DCB 
was termed superior to the plain old balloon angioplasty 
in managing the SB post stent deployment in the main 
branch as per the PEPCAD-BIF trial. Contrary to this, 
DCB in both MB and SB was inferior to DES as per 
DEBUIT and BABILON trials (Table 5) [5]. 
Use of Bioresorbable Vascular Scaffolds to Treat 
BIFs 
Bioresorbable Scaffolds (BVS) were introduced as a 
newer paradigm for coronary artery disease treatment 
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permitting temporary vessel support and drug delivery. 
However, precise recommendations involving the use of 
BVS for treating bifurcation lesions are lacking due to 
their initial avoidance in addressing the subset of this 
patient population [35]. 
Also, a number of disadvantages are linked with the use 
of BVS at bifurcation lesions. Firstly, the free use of the 
device in patients presenting with bifurcations, arrive at 
the cost of distressingly high rates of early device 
thrombosis. Also, BVS has thicker and broader struts 
than metallic stents, rendering a more bulky device. 
There are also constraints on post-dilation techniques, 
which are crucial elements of modern bifurcation PCI, 
as polymeric struts may break more easily, limiting their 
expansion capacity [5]. 
DISCUSSION AND CONCLUSION 
Coronary bifurcation lesions are still challenging as far 
as their treatment is concerned. The provisional one 
stent approach involving the stenting of the main branch 
seems to be a suitable first-line treatment approach for 
most bifurcation lesions. Still, some lesions require two-
stent approach. The enhanced outcomes with the 
currently available DES for bifurcation lesions suggest 
the ready use of the systemic two-stent approach. 
Also, the dedicated bifurcation stent introduces a new 
treatment approach consisting of state-of-the-art 
technologies into cath labs but requires skilful expertise 
to handle the intricate design of these systems. 
However, long-term data from large volume trials are 
necessary before reaching a definite recommendation 
for their use. Preliminary results with newer devices such 
as drug-coated balloons and bioresorbable vascular 
scaffolds are also impressive but lack sufficient data in 
treating bifurcation lesions.  
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